Effects of Sparsentan After Maximized Angiotensin Receptor Blocker (ARB) Treatment in Patients With IgA Nephropathy (IgAN) in the PROTECT Trial

Kidney Outcomes and the Effect of Proteinuria in Alport Syndrome: A Longitudinal Analysis Using Data From the National Registry of Rare Kidney Diseases (RaDaR)

Patients in DUPLEX Achieved Partial or Complete Remission of Proteinuria Earlier and More Often With Sparsentan vs Irbesartan: Implications for Slowing Progression to Kidney Failure in Focal Segmental Glomerulosclerosis (FSGS)

Implications of Proteinuria Remission on Estimated Glomerular Filtration Rate Trajectory in Patients With IgA Nephropathy in PROTECT

Improving Proteinuria With Sparsentan (SPAR) in Patients With IgA Nephropathy (IgAN): A Case Series 

Patient-Reported Outcomes in Rare Kidney Disease Clinical Trials: Sparsentan Versus Irbesartan

Sparsentan in Combination With Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients With IgA Nephropathy (IgAN): A Case Series

Concomitant Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors in Adults With IgA Nephropathy in the Ongoing Phase 2 SPARTACUS Trial